Melane Sampson, Author at BioTuesdays

Developments

UACC initiates study of Fennec’s PEDMARK for AYA and adult cancers

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection...

April 7, 2026

Developments

NervGen completes EOP2 meeting and aligns with FDA on Phase 3 study

NervGen Pharma (NASDAQ: NGEN) has announced the completion of a successful end-of-Phase 2 (EOP2) meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for...

April 7, 2026

Feature

Cell Technologies targeting joint disease with stem cell-based therapies

Closely held Cell Technologies is advancing regenerative medicine through proprietary autologous and allogeneic stem cell platforms designed to treat the pain and inflammation associated with osteoarthritis (OA) and...

April 7, 2026

Developments

Vyome to present compelling data on treatment for MFW at AACR

Vyome Holdings (NASDAQ: HIND) has announced it will present its full Phase 2 investigator-initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor...

April 6, 2026

Developments

Medicus submits study design to FDA for Teverelix in AURr

Medicus Pharma (NASDAQ: MDCX) has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention (AURr) in men...

April 6, 2026

Developments

FDA clears Stereotaxis’ Synchrony system

Stereotaxis (NYSE: STXS) has received FDA 510(k) clearance for its Synchrony system, designed to digitize and modernize the interventional cath lab. According to Stereotaxis, Synchrony is made available with SynX, a...

April 6, 2026

Developments

PureTech’s Seaport reports positive data from trial of GlyphAgo in GAD

PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of...

April 2, 2026

Developments

Adagene and Incyte collaborate to evaluate combination therapy in MSS CRC patients

Adagene (NASDAQ: ADAG) and Incyte (NASDAQ: INCY) have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with...

April 2, 2026

Developments

EBMT journal publishes findings from MaaT’s CHRONOS study in 3L aGvHD

MaaT Pharma (EURONEXT: MAAT) announced the publication of CHRONOS, a large, multicenter, retrospective cohort study evaluating real-world outcomes of third-line (3L) systemic therapies, excluding microbiotherapy, in 59...

April 1, 2026

Executive Moves

Evotec appoints Dr. Ashiq H. Khan as CCO

Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has appointed Dr. Ashiq H. Khan as EVP global head, chief commercial officer (CCO). Dr. Khan brings more than 15 years of international leadership experience in...

April 1, 2026

Author - Melane Sampson

UACC initiates study of Fennec’s PEDMARK for AYA and adult cancers

NervGen completes EOP2 meeting and aligns with FDA on Phase 3 study

Cell Technologies targeting joint disease with stem cell-based therapies

Vyome to present compelling data on treatment for MFW at AACR

Medicus submits study design to FDA for Teverelix in AURr

FDA clears Stereotaxis’ Synchrony system

PureTech’s Seaport reports positive data from trial of GlyphAgo in GAD

Adagene and Incyte collaborate to evaluate combination therapy in MSS CRC patients

EBMT journal publishes findings from MaaT’s CHRONOS study in 3L aGvHD

Evotec appoints Dr. Ashiq H. Khan as CCO

Subscribe